Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Non-Current Assets: 2019-2025

Historic Other Non-Current Assets for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to $1.4 million.

  • Keros Therapeutics' Other Non-Current Assets changed negligibly% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.1 million for FY2024, which is 0.19% up from last year.
  • Keros Therapeutics' Other Non-Current Assets amounted to $1.4 million in Q3 2025, which was down 0.00% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Other Non-Current Assets registered a high of $2.1 million during Q4 2024, and its lowest value of $115,000 during Q1 2021.
  • Over the past 3 years, Keros Therapeutics' median Other Non-Current Assets value was $1.4 million (recorded in 2025), while the average stood at $1.5 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first spiked by 1,054.78% in 2021, then fell by 8.67% in 2023.
  • Keros Therapeutics' Other Non-Current Assets (Quarterly) stood at $1.3 million in 2021, then remained steady at $1.3 million in 2022, then spiked by 54.63% to $2.1 million in 2023, then climbed by 0.19% to $2.1 million in 2024, then remained steady at $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.4 million for Q2 2025, and $1.4 million during Q1 2025.